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Review Article
Therapeutic hypothermia for acute ischemic
stroke: ready to start large randomized trials?
H Bart van der Worp1,4, Malcolm R Macleod2,4 and Rainer Kollmar3, for the European
Stroke Research Network for Hypothermia (EuroHYP)
1Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht,
Utrecht, The Netherlands; 2Division of Clinical Neurosciences, Centre for Clinical Brain Sciences, University
of Edinburgh, Edinburgh, UK; 3Department of Neurology, University Hospital of Erlangen, Erlangen, Germany
Therapeutic hypothermia is a means of neuroprotection well established in the management of
acute ischemic brain injuries such as anoxic encephalopathy after cardiac arrest and perinatal
asphyxia. As such, it is the only neuroprotective strategy for which there is robust evidence for
efficacy. Although there is overwhelming evidence from animal studies that cooling also improves
outcome after focal cerebral ischemia, this has not been adequately tested in patients with acute
ischemic stroke. There are still some uncertainties about crucial factors relating to the delivery of
hypothermia, and the resolution of these would allow improvements in the design of phase III
studies in these patients and improvements in the prospects for successful translation. In this
study, we discuss critical issues relating first to the targets for therapy including the optimal depth
and duration of cooling, second to practical issues including the methods of cooling and the
management of shivering, and finally, of factors relating to the design of clinical trials.
Consideration of these factors should inform the development of strategies to establish beyond
doubt the place of hypothermia in the management of acute ischemic stroke.
Journal of Cerebral Blood Flow & Metabolism (2010) 30, 1079–1093; doi:10.1038/jcbfm.2010.44; published online
31 March 2010
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Introduction
Therapeutic hypothermia (TH) is one of the most
promising treatment strategies for acute ischemic
stroke for several reasons. It is the only neuroprotec-
tive treatment proven effective in large randomized
trials in patients with acute brain injury (HACA,
2002; Bernard et al, 2002; Jacobs et al, 2007). Animal
studies indicate a robust benefit of hypothermia after
focal cerebral ischemia (van der Worp et al, 2007),
without indicating critical publication bias (Sena
et al, 2010). Moreover, in contrast to most other
neuroprotective treatment strategies, multimodal
pathophysiological effects on the ischemic cascade
have been described. In contrast, TH has only been
rudimentarily studied in stroke patients (Kollmar
and Schwab, 2009). So far, no large randomized
multicenter trial has been started. The reasons for the
lack of appropriate studies may be multifactorial. First
of all, no device or pharmacological company has
provided sufficient sponsoring for such trials, nor did
the government. In accordance, hypothermia in
investigator-initiated trials has to compete with trials
of the pharmacological industry. In addition, there are
more questions than answers about the appropriate
elements for TH as a treatment for stroke. Both animal
and clinical data on hypothermia in focal cerebral
ischemia are reviewed in this study, addressing
research questions for future large trials.
Supporting animal data
After ischemia, neurons may die as a result of
necrosis and apoptosis (Dirnagl et al, 1999). Impor-
tant intermediate events include energy depletion,
excitotoxicity, calcium influx, free radical formation,
and inflammation. Immediately after vessel occlu-
sion, a central core of very low perfusion is
surrounded by an area with dysfunction from
metabolic and ionic disturbances, but in which
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structural integrity is still preserved, the so-called
ischemic penumbra (Astrup et al, 1981). This is why
immediate clinical deficits do not necessarily reflect
irreversible damage, and for this reason, the penum-
bra is the major treatment target in acute ischemic
stroke. Depending on residual blood flow and
duration of ischemia, the penumbra will eventually
be incorporated into the infarct if reperfusion is not
achieved. Most of the irreversible damage is inflicted
in the first few hours after the onset of ischemia, but
pathologic processes may continue for several days
(Dirnagl et al, 1999), and in patients, the penumbral
tissue has been found for up to 48hours of ischemic
stroke onset (Donnan et al, 2009).
On the basis of the concept of a salvageable
ischemic penumbra, B500 ‘neuroprotective’ treat-
ment strategies have shown to improve outcome in
animal models of acute ischemic stroke (O’Collins
et al, 2006). In contrast, only very early intravenous
thrombolysis with recombinant tissue plasminogen
activator (rt-PA) and aspirin have proven to be
efficacious in patients, despite numerous clinical
trials of other treatment strategies in acute ischemic
stroke (van der Worp et al, 2007; Donnan et al, 2008).
One of the reasons for the failure of allegedly
neuroprotective compounds in patients may be that
most of them inhibit only a single step in the chain of
events leading to cell death (STAIR, 1999; Gladstone
et al, 2002).
Animal models of focal or global cerebral ischemia
have suggested that hypothermia affects a wide range
of cell death mechanisms, including energy deple-
tion, disruption of the blood–brain barrier, free radical
formation, excitotoxicity, and inflammation (Zhao
et al, 2007; Yenari et al, 2008). Possibly mediated
through these multiple and synergistic effects, the
benefit of hypothermia in animal models is more
consistent and robust than that of any other treatment
strategy. In a systematic review and meta-analysis of
animal studies of focal cerebral ischemia, including
data obtained from a total of 3,353 animals, hypother-
mia reduced the infarct size by 44% (95% confidence
interval, 40% to 47%) (van der Worp et al, 2007).
Reports on the efficacy of potential treatment
strategies in animal models of stroke seem to be
profoundly biased by the methodological quality of
the studies, which may have contributed to the failure
of the translation of these studies to the clinic (Sena
et al, 2007a). Hypothermia is no exception. For
example, in the systematic review, efficacy was
significantly lower compared with random treatment
allocation and blinded assessment of outcome than in
those without. However, hypothermia still reduced
the infarct size by B40% in studies of adequate
methodological quality, lending support to a true
benefit of this therapy (van der Worp et al, 2007).
There is empirical evidence that animal studies of
ischemic stroke that report positive or significant
results are more likely to be published. Such
publication bias will lead to overestimation of
treatment effects and can render the readily available
evidence unreliable for decision making. It has been
estimated that because of publication bias, the above-
mentioned meta-analysis overstated the effect of
hypothermia by B8% (Sena et al, 2010). Even after
adjustment for this effect of publication bias, the
benefit of hypothermia remains substantial.
The success of translation of animal studies to the
clinic may in part depend on the diversity of species
in which a particular treatment strategy was tested,
and on the testing in animals with comorbidities
relevant to the disease under study (STAIR, 1999;
Gladstone et al, 2002). Unfortunately, of the 222
experimental comparisons in the systematic review,
214 (96%) involved rats, making any conclusion on
differences in efficacy between species futile. The
same applies to the effect of sex: 196 comparisons
(89%) concerned male animals and 3 (1%) female
animals, whereas in 21 comparisons (9%), the sex
was unknown. In contrast to patients with stroke,
animals in studies of focal cerebral ischemia are
generally young (van der Worp et al, 2005). The
effect of hypothermia has only recently been
tested in 17-month-old rats, and has proven to be
consistent with the results of the meta-analysis
(Florian et al, 2008). In the systematic review,
hypothermia was slightly more effective in hyper-
tensive than in normotensive animals, but to date,
just a single study has tested the effect in diabetic
rats, preventing a robust conclusion on a potential
interaction between hypothermia and diabetes
mellitus (van der Worp et al, 2007).
Despite the above-mentioned limitations, we be-
lieve that hypothermia has been studied in sufficient
detail and under a sufficiently broad variety of
experimental conditions in animal models of is-
chemic stroke to support the translation of this
treatment strategy to clinical trials.
What should the aims of therapy be?
Optimal Target Temperature
In the above-mentioned systematic review of animal
studies, the benefit of hypothermia was inversely
related to the temperature achieved (Figure 1).
Hypothermia reduced the infarct size by > 40% with
temperatures of 341C or below, but the infarct size
was still reduced by 30% (95% confidence interval,
21% to 39%) with cooling to 351C (van der Worp
et al, 2007), suggesting that even very modest cooling
has considerable potential as a neuroprotective
strategy. A later study not included in this review
compared cooling with 36, 35, 34, 33, and 321C for
4 hours, starting 90minutes after middle cerebral
artery (MCA) occlusion in rats, with normothermia
(371C). Only cooling to 34 and 331C improved
outcome, with the largest benefit obtained at 341C,
suggesting that this is the optimal target temperature
for hypothermia in acute ischemic stroke (Kollmar
et al, 2007). However, because this is only a single
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study with data not entirely consistent with those of
the meta-analysis, these results should be interpreted
with some caution.
Most early controlled and uncontrolled studies of
hypothermia in acute ischemic stroke (Schwab et al,
1998, 2001; Georgiadis et al, 2001; Krieger et al, 2001;
De Georgia et al, 2004), as well as most randomized
trials of hypothermia in postanoxic encephalopathy
after cardiac arrest (Bernard et al, 2002; HACA,
2002), perinatal hypoxic-ischemic encephalopathy
(Jacobs et al, 2007), and traumatic brain injury
(Hutchison et al, 2008; Peterson et al, 2008) have
tested cooling to levels of 321C to 341C. Unfortu-
nately, discomfort and shivering increase with lower
temperatures, and cooling to these levels therefore
generally requires sedation, mechanical ventilation,
and admission to an intensive care unit (ICU)
(Polderman and Herold, 2009). Owing to the limited
availability of intensive care beds in most countries,
treatment of even a minority of acute stroke patients
is therefore precluded by substantial practical and
logistical problems. The fact that intensive care
treatment has long been a common clinical practice
for patients with severe traumatic brain injury or
after cardiac arrest may explain why large rando-
mized clinical trials of moderate hypothermia have
been accomplished in these patient populations,
whereas such trials have not even been started in
patients with acute ischemic stroke.
In addition to the logistical barriers imposed by
decreasing temperatures to 341C or below, side
effects of hypothermia also appear to occur more
frequently with each degree Celsius reduction in
temperature. For example, cardiac arrhythmias be-
come more frequent with temperatures below 301C,
platelet dysfunction occurs when temperatures
decrease below 351C, and coagulation is reduced
with temperatures below 331C (Polderman and
Herold, 2009).
Temperature reductions to 35.5 or 351C have been
shown to be feasible and safe in awake patients with
acute ischemic stroke by surface cooling, in combi-
nation with pethidine (meperidine) to treat shivering
(Kammersgaard et al, 2000). Using a similar strategy,
body temperature could be reduced to 34.51C in
awake patients with acute myocardial infarction (Ly
et al, 2005). Therefore, cooling to 351C seems to be a
feasible strategy to be tested in large randomized
trials. The NOCSS (Nordic Cooling Stroke Study)
was a randomized trial which tested the effect of
temperature reduction to 351C in awake patients
with surface cooling for 9hours, started within
6hours of the onset of ischemic stroke. Unfortu-
nately, the trial was terminated because of slow
recruitment after the inclusion of 44 patients against
a target of 1,000 patients, and results have not yet
been published (http://www.strokecenter.org, as-
sessed on 2 November 2009). The ICTuS-L (Intravas-
cular Cooling for the Treatment of Stroke—Longer
window) trial is a phase II trial designed to investigate
the feasibility and safety of a combination of intrave-
nous thrombolysis and intravascular cooling to 331C
in awake patients with ischemic stroke (Guluma et al,
2006). The trial has recently been terminated and
publication of the results is expected shortly.
It is noteworthy that even the maintenance of
normothermia in the first few days after stroke onset
may improve outcome. In the randomized PAIS
(Paracetamol (Acetaminophen) In Stroke) trial, treat-
ment of patients with a baseline body temperature of
371C or above with high-dose paracetamol, started
within 12hours of stroke onset and continued for 3
days, resulted in a temperature reduction of just
0.31C at 24hours, and also in an improved outcome
at 3 months (Den Hertog et al, 2009b). Although
biologically plausible, this finding requires confir-
mation in a second randomized trial as this was
observed in a post hoc subgroup analysis.
As cooling to 33 or 341C may be more effective
than to 351C, there is a strong need to compare the
feasibility and safety of cooling with these levels in
patients with acute ischemic stroke. Two of such
small phase II trials have just started in Germany
(http://www.strokecenter.org/Trials/TrialDetail.aspx?-
tid=883) and Finland (http://www.strokecenter.org/
Trials/TrialDetail.aspx?tid=949).
Duration of Cooling
In animal models of focal cerebral ischemia, the
diverse pathophysiological processes that are in-
voked exert their deleterious effects over different
time courses extending from the first hours to several
days after vessel occlusion (Dirnagl et al, 1999).
Such observations would suggest that hypothermia
should in fact be more efficacious if prolonged. In the
Figure 1 Effect of target temperature on the efficacy of
hypothermia in improving infarct volume in animal models of
stroke. Vertical error bars represent 95% confidence intervals at
each point, and the gray bar represents the 95% confidence
interval for the overall estimate of efficacy. Adapted from van der
Worp et al (2007).
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above-mentioned meta-analysis, there was a small
and unexpected inverse relationship between the
duration of hypothermia and effect size (Figure 2).
However, 193 of the 277 (70%) individual experi-
ments tested hypothermia for r3hours, and just 32
(12%) the effect of hypothermia for > 12hours,
precluding firm conclusions about the relative
benefit of longer cooling. In addition, the two
individual studies that compared the effect of
cooling for Z12hours with cooling for r3hours
found a considerably larger benefit with these
longer treatment durations (Yanamoto et al, 1996,
1999). In a recent study of cooling to 331C initiated
1hour after permanent MCA occlusion in rats,
hypothermia for 48 hours seemed to provide better
functional and morphologic outcomes than hy-
pothermia for 24 or 12hours, with the smallest
effects observed with the shortest duration of cooling
(Clark et al, 2008).
In clinical trials of cardiac arrest, hypothermia has
been proven efficacious if maintained for 12 (Bernard
et al, 2002) or 24hours (HACA, 2002). In none of these
two trials, a well-founded reason for the selection of
these treatment durations was provided, and reports
of pilot studies suggest that this was not much more
than an educated guess (Zeiner et al, 2000).
In short, there is no adequate information on the
optimal duration of hypothermia in patients with
acute ischemic stroke, and this may even depend on
the severity of ischemia and on the occurrence of
reperfusion. On theoretical grounds, longer dura-
tions may be more effective, but these may also be
less well tolerated by awake patients and may be
associated with a higher risk of complications. One
small phase II trial is currently comparing the
feasibility of cooling for 12 and 24hours in patients
with acute ischemic stroke.
Time Window for Starting Hypothermia
In preclinical studies, time is the most critical factor
in the treatment of cerebral ischemia (Dirnagl et al,
1999). A pooled analysis of six randomized trials of
intravenous thrombolysis with rt-PA has also
strongly suggested a greater benefit the sooner
treatment was started, with potential efficacy up to
6hours after stroke onset (Hacke et al, 2004).
Expediting the delivery of care should therefore be
a crucial factor in any acute stroke trial.
In animal studies, the effect of hypothermia was
most consistent when treatment was started before or
at the onset of focal cerebral ischemia, but the benefit
remained substantial with treatment delays of up to
6hours, without a clear time dependency (Figure 3).
Both the number of experiments with treatment
delays of > 3hours and the number of animals
included in these experiments were too small to
draw firm conclusions (van der Worp et al, 2007). In
individual studies testing the effect of delaying the
start of cooling, the benefit of hypothermia subsided
more strongly over time than suggested by the results
of the meta-analysis. In these studies, a statistically
significant benefit was not observed anymore at
45minutes (Markarian et al, 1996), or at 2 (Baker
et al, 1992), 3 (Maier et al, 2001), or 6 hours (Ren
et al, 2004; Ohta et al, 2007). This discrepancy may
reflect pitfalls of the meta-analysis, the individual
studies, or both, or may reflect true differences in
windows of therapeutic opportunity between species
or strains, different durations of ischemia, or differ-
ent temperatures.
In the European Hypothermia After Cardiac Arrest
Study, cooling improved functional outcome despite
a median interval of 8 hours between the restoration
of spontaneous circulation and the attainment of the
Figure 2 Effect of duration of cooling on the efficacy of
hypothermia in improving infarct volume in animal models of
stroke. Vertical error bars represent 95% confidence intervals at
each point, and the gray bar represents the 95% confidence
interval for the overall estimate of efficacy. Adapted from van der
Worp et al (2007).
Figure 3 Effect of delay to initiation of treatment on the efficacy
of hypothermia in improving infarct volume in animal models of
stroke. Vertical error bars represent 95% confidence intervals at
each point, and the gray bar represents the 95% confidence
interval for the overall estimate of efficacy. Adapted from van der
Worp et al (2007).
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target temperature (HACA, 2002). There are no data
on the maximum time to start efficacious cooling in
patients with acute ischemic stroke. However, it is
expected that a potential benefit will be greater the
earlier cooling is started.
On the first day after stroke onset, spontaneous
reperfusion occurs in only a minority of the
patients (Jorgensen et al, 1994; Bowler et al, 1998).
Even after intravenous thrombolysis, complete reca-
nalization of an occluded MCA 2hours after start of
treatment is found only in up to one-third of patients
(Alexandrov et al, 2004; Molina et al, 2006). In the
first few hours after stroke onset, most infarcts will
therefore still lack adequate perfusion. For a novel
treatment strategy to be successful, this strategy
should either lead to a higher rate of recanalization
or be effective independent of the occurrence of
reperfusion. In animal models, the benefit of
hypothermia was larger in temporary than in
permanent occlusion models, but the effect in the
latter was still substantial (37%; 95% confidence
interval, 30% to 43%). In temporary occlusion
models, the benefit was largest when cooling was
started before or during ischemia, but also substan-
tial when started during reperfusion (van der Worp et
al, 2007). Hypothermia is therefore a promising
treatment strategy with or without the achievement
of reperfusion.
Practicalities of the delivery of
hypothermia
The Method of Cooling
Two major methods for inducing systemic hypother-
mia in stroke patients can be distinguished: surface
cooling and endovascular cooling (Polderman and
Herold, 2009). In general, surface cooling methods
have the advantage of being noninvasive, and are
therefore probably applicable on a larger scale, as
experience with introducing catheters in large veins
is not required. In addition, their noninvasive nature
probably allows the combination of hypothermia
with concurrent thrombolysis. However, as the
body’s natural response to heat loss consists of an
increase in sympathetic tone and vasoconstriction of
vessels in the skin, maintenance of hypothermia at
the target temperature may be more difficult with
surface cooling than with endovascular cooling, and
patient discomfort and shivering may be more
difficult to prevent (Polderman and Herold, 2009;
Sessler, 2009a). Simple and relatively inexpensive
surface cooling techniques include the use of fans,
convective air blankets, water mattresses, and alco-
hol bathing. However, these methods have a low-to-
intermediate speed of cooling and are generally labor
intensive. A more rapid induction of hypothermia
can be obtained using ice packs, but temperature
cannot be controlled sufficiently during the main-
tenance and rewarming phases. Automated surface
cooling systems have relatively high cooling rates
and temperature can be controlled throughout all
phases.
Endovascular cooling is generally faster and
patient comfort may be greater if warming blankets
are applied. Disadvantages are its invasive nature,
leading to time loss and preventing hypothermia
concurrent with thrombolysis, and the required
experience with endovascular techniques, prevent-
ing an easy wide-spread application (Polderman and
Herold, 2009).
For a more rapid induction of hypothermia, chilled
intravenous fluids (e.g., normal saline at 41C, 20 to
30mL/kg body weight in 30minutes) may be infused
at the onset of surface or endovascular cooling. In
patients with postanoxic encephalopathy, subarach-
noid hemorrhage, or traumatic brain injury, the
infusion of large volumes of fluids is generally
tolerated well (Baumgardner et al, 1999; Bernard
et al, 2003; Polderman et al, 2005), and a recent small
study has suggested that this is also safe in patients
with acute stroke (Baumgardner et al, 1999; Bernard
et al, 2003; Polderman et al, 2005; Kollmar et al,
2009b).
Selective head (and neck) cooling using helmets,
head caps, and neck bands may have the advantage
of avoiding systemic complications and has been
tested in sedated patients with traumatic brain injury
(Wang et al, 2004; Qiu et al, 2006) or after cardiac
arrest (Wandaller et al, 2009). However, these
methods appear less feasible in awake patients with
acute stroke and have not been tested in this patient
population. In addition, the target temperature is
hard to assess and control during all phases of the
cooling process, as this requires invasive monitoring.
In a modeling study, temperatures below 361C could
not be reached in the deep brain tissue with head
cooling alone, whereas additional application of
neckbands covering the carotid bifurcation did lead
to a considerable temperature reduction in the deep
brain tissue. Temperature sensors had to be applied
at least 2 cm below the cortical surface to yield values
representative for deep brain tissue (Keller et al,
2009). Selective brain cooling with cold saline
circulating in balloon catheters introduced into the
nasal cavity has been shown to be feasible in pigs
(Covaciu et al, 2008), but is still awaiting clinical
studies.
As mentioned above, surface cooling has been
shown to be feasible in awake patients with ischemic
stroke with target temperatures ofB351C (Kammers-
gaard et al, 2000). Cooling awake stroke patients to
331C for a total of 24 hours has been shown to be
possible with an endovascular device in the inferior
vena cava, and a combination of buspirone, meper-
idine, and cutaneous warming with a heating blanket
to suppress shivering (Guluma et al, 2006). There are
no randomized trials in which the safety, feasibility,
and speed to target temperature of surface and
endovascular cooling have been compared in awake
patients.
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Where Should Cooling be Performed?
As mentioned above, all successful cooling trials in
patients with ischemic brain injury were performed
in an ICU. However, the number of beds attributed to
neurology in ICUs is relatively small worldwide, and
even in countries with a highly organized stroke
management structure such as Germany, the number
of beds in special neurologic ICUs is only 500,
whereas the annual incidence of stroke in Germany
is B250,000 individuals (Kolominsky-Rabas and
Heuschmann, 2002). The number of stroke units
(SUs) is increasing and 161 SUs with a capacity of up
to 20 beds have been identified in Germany
(Deutsche Schlaganfall Hilfe). As a consequence,
treatment strategies for stroke should be safe and
feasible for use in regular SUs. As mentioned
above, cooling to 35.51C has been shown to be
feasible in an SU (Kammersgaard et al, 2000), but
whether this also applies to lower temperatures
remains to be seen.
Preventing Shivering and Discomfort
Humans have an effective thermoregulatory system
which opposes the induction and maintenance of
hypothermia (Sessler, 2009b). In particular, shivering
and peripheral vasoconstriction counteract cooling
(Delaunay et al, 1993; Cheng et al, 1995), and are
accompanied by sympathetic activation, tachycardia,
and hypertension (Frank et al, 1997; Frank et al,
1999). These may lead to discomfort (Mokhtarani
et al, 2001), and a stressful autonomic response may
also be dangerous in critically ill patients.
Human thermoregulatory mechanisms comprise
sensory inputs, a central control system, and efferent
systems which act to increase or decrease tempera-
ture to keep this in the normal range (Lopez et al,
1994; Cheng et al, 1995; Sessler, 2009b). Body
temperature is controlled by the hypothalamus by
autonomic reactions, such as sweating and cuta-
neous vasodilation to decrease temperature, and
cutaneous arterio-venous shunt constriction and
shivering to increase temperature. Heat distribution
is not uniform (Sessler, 2009b), with the trunk and
head forming a core compartment with homogenous
temperature because of high perfusion within the
body and the arms and legs being 21C to 41C colder
than the core and having substantial internal tem-
perature gradients (Rajek et al, 2000). The contribu-
tion of the skin temperature to thermoregulatory
control depends on the defense mechanism. Skin
temperature contributes B10% to control of sweat-
ing, and B20% to control of vasoconstriction and
shivering. Autonomic responses are therefore largely
based on alterations in core temperature (Sessler,
2009b).
General anesthesia fundamentally impairs thermo-
regulatory defense (Schwab et al, 1998; Sessler,
2009b), but the induction and maintenance of
hypothermia is a major challenge in awake indivi-
duals for whom such mechanisms are intact. In a
small study in stroke patients, vasoconstriction and
shivering thresholds were 37.11C±0.41C and
36.61C±0.41C, respectively (Zweifler and Sessler,
1996). Peripheral vasoconstriction due in part to
hypothermia-induced increases in serum catechola-
mines (Frank et al, 1997) leads to isolation of the
body core and thereby preserves metabolic heat
(Matsukawa et al, 1995). Unfortunately, this im-
paired perfusion may limit the efficiency of surface
cooling.
Shivering is another autonomic response to hy-
pothermia and leads to metabolic heat production
(Horvath et al, 1956). The shivering threshold is
normally set at B35.51C, which is B11C below the
vasoconstriction threshold (Lopez et al, 1994).
Physical and pharmacological approaches to prevent
and/or treat shivering and vasoconstriction have
been reviewed in detail elsewhere (Sessler, 2009a)
and are discussed briefly below.
Pharmacological Strategies Against Shivering: The
opioid meperidine (pethidine) is frequently used
(Zweifler and Sessler, 1996; Mokhtarani et al, 2001;
Lyden et al, 2005; Kollmar et al, 2009b), and at high
doses, reduced the shivering threshold in healthy
volunteers to 33.41C (Mokhtarani et al, 2001).
Unfortunately, it has a wide range of side effects,
including nausea and sedation. Other drugs which
might be useful alone or in combination include
magnesium (Zweifler et al, 2004; Meloni et al,
2009), clonidine, and dexetomidine (Delaunay et al,
1993; Talke et al, 1997; De Witte et al, 1998).
For example, low-dose buspirone and low-dose
meperidine act synergistically to reduce the shiver-
ing threshold, while causing little sedation or
respiratory insufficiency (Mokhtarani et al, 2001),
and this combination has recently been used in
patients with acute stroke (Lyden et al, 2005; Kollmar
et al, 2009b).
Physical Methods Against Shivering: As skin tem-
perature contributesB20% to the autonomic control
of shivering (Lenhardt et al, 1999), surface cooling
might lead to greater discomfort and more severe
shivering and vasoconstriction than endovascular
cooling. Local skin counter warming may blunt this
effect (Mekjavic and Eiken, 1985; Iaizzo et al, 1999;
Kimberger et al, 2007), with each 11C increase in
mean skin temperature decreasing the shivering
threshold by 0.251C (Cheng et al, 1995). Effects of
counter warming have been reported in nonsedated
volunteers (Iaizzo et al, 1999; Sweney et al, 2001) as
well as in sedated and ventilated brain injury
patients (Badjatia et al, 2009), but are not consistent
(Doufas et al, 2003). A combination of pharmacolo-
gical and physical techniques is attractive, and in
healthy volunteers, meperidine plus skin counter
warming reduced the shivering threshold to below
341C without significant side effects (Kimberger et al,
2007).
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Temperature Measurement
Any cooling strategy will involve measurement of
temperature, even if only to show that cooling has
been achieved. Often, however, the cooling strategy
will require that temperature feedback is provided to
the cooling device to allow adjustment of the
intensity of cooling and thereby stability at target
temperature and control of rewarming. It is pre-
sumed that any benefit of hypothermia is manifest
through direct effects on ischemic brain tissue (and
in particular in the ischemic penumbra), rather than
through indirect effects on, for instance, the systemic
inflammatory response. The primary temperature of
interest is therefore the temperature in the region of
the infarct. At equilibrium, any systemic measure of
temperature would be appropriate, but in the context
of active cooling and controlled rewarming, there
may be differences between brain and systemic
temperatures, which must be taken into account in
planning the best peripheral temperature measure-
ment to be used. A further consideration relates to
the delivery of cooling to the affected brain; in
patients with ischemic stroke in whom no reperfu-
sion has occurred, cerebral blood flow (CBF), and
thereby delivery of cooling to the affected brain
tissue, is by definition compromised.
How can we demonstrate that cooling the body
cools the infracted brain? Measurement of brain
temperature in vivo has until recently required direct
instrumentation of brain substance, for instance,
using intracranial probes. These are seldom used
routinely in patients with stroke, and given the
potential associated morbidity, their use in a research
context is limited. However, in a small group of
patients with large space-occupying MCA stroke
treated with moderate hypothermia wherein brain
temperature was measured directly, this decreased to
33.31C when body temperature was cooled to 331C
(Schwab et al, 1998). Magnetic resonance spectro-
scopic thermometry is a technique that exploits
temperature-dependent changes in the separation of
peaks in magnetic resonance spectroscopy to report
changes in temperature in a volume of brain
(Karaszewski et al, 2006). Although the ability to
measure absolute temperature with precision is still
in some doubt, it is certainly possible to measure
differences in temperature (e.g., between the non-
infarcted hemisphere, ischemic core, and penumbra)
with some precision. Temperature can be reported in
voxels of 8mm3 across two different slices with an
acquisition time of only 8minutes, making this
practicable in the emergency situation in patients
undergoing active cooling. The Edinburgh HAIST
(Hypothermia in Acute Ischemic Stroke Trial) will
measure ischemic core and penumbral temperatures
2 to 3hours after the initiation of cooling in patients
with acute ischemic stroke, seeking to show that
cooling the body does indeed cool the brain.
What is the best peripheral temperature measure-
ment to monitor cooling? The optimal peripheral
temperature measurement will provide continuous
feedback to the cooling device to allow adjustment of
cooling intensity, and hence candidate measures
include esophageal, rectal, or bladder temperature
probes. Bladder probes are probably least invasive
(many patients will already have a urinary catheter
in situ), but have the potential disadvantage that ice-
cold saline rapidly infused may be rapidly cleared by
the kidneys, therefore giving inappropriate tempera-
ture readings in the early stages of cooling and
potentially leading to an overshoot of hypothermia.
Rectal probes have the disadvantage that there may
be a substantial delay between changes in core
temperature and changes in rectal temperature.
Although esophageal temperature probes probably
give the most precise and dynamic indication of core
temperature, they are also the most invasive approach.
In the same manner that bladder temperature probes
also function as urinary catheters, it may be that
esophageal probes that also function as nasogastric
tubes might be developed for this purpose.
Acid–Base Management: The Role of CO2
Mechanoregulatory mechanisms maintain near-con-
stant CBF over a wide range of cerebral perfusion
pressures (Lavi et al, 2003). The vascular tone is also
regulated through chemoregulation by endothelial
nitric oxide. Levels of endothelial nitric oxide are
regulated by local metabolic activity, pH, and pCO2,
with PaCO2 being the most potent known vasodila-
tor; global changes in PaCO2 can easily overcome
local mechanoregulatory mechanisms and therefore
influence CBF (Murkin et al, 1987). Both PaCO2 and
PaO2 are strongly influenced by temperature (Mur-
kin, 2007), and their manipulation by changing
proportions of inspired ventilatory gases or by
adjusting ventilation parameters further complicates
the situation. It is therefore somewhat surprising
how little attention has been given to the interaction
between temperature and blood gases in ischemic
stroke (Kollmar et al, 2009a). In ventilated patients,
the standard (a-stat) approach is to maintain PaCO2
at 40mmHg when measured ex vivo at 371C (Murkin,
2007). In contrast, during pH-stat management, the
measured PaCO2 is adjusted to take into account
patient temperature (du Plessis et al, 1997; Kollmar
et al, 2002, 2009a). The a-stat strategy results in a
higher measured PaCO2 leading to increased minute
volume settings, reduced PaCO2, and decreased CBF;
this is avoided with pH-stat management (Murkin,
2007; Figure 4).
These strategies have been compared in a rodent
model of transient focal cerebral ischemia (Kollmar
et al, 2002), in which cooling to 331C was established
during the 5-h reperfusion period. Consistent with
the above hypothesis, CBF was higher and infarct
size was smaller in pH-stat-ventilated animals
compared with a-stat-ventilated animals.
In a nonrandomized study of patients with large
MCA territory ischemic stroke, CBF was substantially
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higher with pH-stat than with a-stat ventilation
(Kollmar et al, 2009a). However, pH-stat ventilation
was associated with critical increases in intracranial
pressure after 3 days, possibly because of effects on
cerebral blood volume, and pH-stat should therefore
be used with caution in patients with space-occupy-
ing hemispheric infarction. Furthermore, the in-
creased PaCO2 occurring with pH-stat may lead to a
steal phenomenon, diverting blood away from the
injured to the healthy brain tissue (Oshima et al,
2000). The clinical importance of these issues needs
to be better understood to guide the use of hypo-
thermia in mechanically ventilated patients.
Other considerations for clinical trial
design
Cooling Patients With Intracerebral Hemorrhage
In animal models of focal cerebral ischemia (van der
Worp et al, 2007; Sena et al, 2007b) and in clinical
trials in stroke (Hacke et al, 2004), efficacy declines
with delay to treatment, and expediting the delivery
of care should therefore be a crucial factor in any
acute stroke trial (Macleod et al, 2003; Thrift et al,
2006). For this reason, cooling may have a larger
effect if started in the field instead of in the
emergency room or in the ward. However, imaging
(computed tomography or magnetic resonance ima-
ging) is required to reliably distinguish ischemic
stroke from intracerebral hemorrhage (ICH); there-
fore, hypothermia can only be initiated in the field if
it does not harm patients with ICH.
However, even mild hypothermia may have effects
on platelet function and coagulation, which could
preclude its use in patients with ICH. In animals,
moderate hypothermia has been associated with
reversible platelet dysfunction, prolonged bleeding,
prothrombin, and partial prothrombin times, and
reduced thromboxane B2 (Valeri et al, 1987; Staab
et al, 1994). In humans, conflicting evidence suggests
that hypothermia may either increase (Zhang et al,
2004; Xavier et al, 2007; Scharbert et al, 2010) or
decrease (Hessel et al, 1980; Yoshihara et al, 1985;
Romlin et al, 2007) platelet function, and further data
are required. These effects may be temperature
dependent, with lower temperatures leading to larger
aberrations (Polderman and Herold, 2009). Rapid
rewarming has been reported to be associated with
lethal disseminated intravascular coagulation
(Mahajan et al, 1981).
Prolonged hypothermia has been reported to
reduce inflammation, edema, and blood–brain bar-
rier in animal models of ICH (Kawai et al, 2001;
Fingas et al, 2007). However, the reported beneficial
effects of mild hypothermia are inconsistent and
depend on the model, severity of the hemorrhage,
and the time of treatment (MacLellan et al, 2009); in
one study, hypothermia increased bleeding and
worsened outcome (MacLellan et al, 2004). There
are limited clinical data on cooling in ICH, but one
small nonrandomized study suggested that mild
hypothermia (351C), started more than 12hours from
ICH onset, and when maintained for 10 days,
appeared to reduce case fatality and was not
associated with recurrent bleeding (Kollmar et al,
unpublished communication).
pH-stat
Blood
volume
Blood
volume
Blood
volume
alpha-stat
Brain tissue
Brain tissue Brain tissue
CSF
CSF CSF
Figure 4 Effects of a- and pH-stat on different intracranial compartments. CSF, cerebrospinal fluid.
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Inflammation and Infections During Hypothermia
Infections have been reported in up to a third of
patients with acute stroke and to be related to poor
functional outcome (Emsley and Hopkins, 2008).
Experimental and clinical studies have shown that
brain injury can lead to a ‘central nervous system
injury-induced immune deficiency syndrome’ (Meisel
et al, 2005). In the mouse, focal cerebral ischemia has
been reported to lead to a reduction in the peripheral
blood lymphocytes count and impaired Tand natural
killer activity, leading to increased pneumonia and
mortality rates (Prass et al, 2003; Meisel et al, 2004).
Decreased peripheral blood lymphocyte count has
also been reported in acute stroke patients, along
with increased expression of proinflammatory, proa-
poptotic, or adhesion-relevant genes in the majority
of peripheral blood mononuclear cells subpopula-
tions (Kassner et al, 2009).
Cooling may accentuate this immunosuppression
(Russwurm et al, 2002), perhaps through a reduction
of cytokine response and the induction of an
antiinflammatory T-cell cytokine profile (Lee et al,
2001). Experimental data suggest that hypothermia is
associated with reduced inflammation in ischemic
brain regions (Zhao et al, 2007), and this may be one
reason for its protective effects. However, if this
immunosuppression is more general, it may predis-
pose to infectious complications and may thereby be
associated with an increased length of hospital stay,
poor outcome, and increased mortality. In patients
with space-occupying hemispheric infarction treated
with induced hypothermia, pneumonia rates of up to
83% have been reported (Schwab et al, 1998, 2001;
Georgiadis et al, 2001, 2002), but these may be
explained in large part by sedation, mechanical
ventilation, and the use of muscle relaxants. In
patients with acute stroke, the use of mechanical
ventilation should probably be restricted because of
the risk of ventilator-associated pneumonia (Porze-
canski and Bowton, 2006). In all, 10% to 20% of
patients who were mechanically ventilated for
> 48hours develop ventilator-associated pneumonia,
with mortality rates of 15% to 50%, and ICU length
of stay in patients with ventilator-associated pneu-
monia is increased by a mean of 6 days and leads to
an increase in treatment costs (Safdar et al, 2005).
Data for infection rates in stroke patients treated
with hypothermia without mechanical ventilation
are limited. Although many studies report a trend
toward more pneumonia in the hypothermia group
(Kammersgaard et al, 2002; Knoll et al, 2002; De
Georgia et al, 2004), these results should be inter-
preted with caution because of the small numbers of
patients included and the lack of a standard defini-
tion of pneumonia.
Each of stroke, cooling itself, the sedative medica-
tion used to prevent shivering, and mechanical
ventilation may therefore increase the risk of infec-
tion (Polderman and Herold, 2009). This might
be reduced by limiting the duration of cooling.
Kammersgaard et al (2002) showed that with 6hours
of cooling, infection rates were only slightly higher
than in the normothermia group, and in patients
with myocardial infarction treated with mild hy-
pothermia for 4 hours using a standard antishivering
approach, there was no increased pneumonia (Dixon
et al, 2002; Kandzari et al, 2004; Table 1). Similarly,
limiting the depth of hypothermia to 351C might
reduce the risk of infection both directly and through
lower requirements for sedation (Mokhtarani et al,
2001), but both of these approaches are likely to lead
to reduced neuroprotection. Clinical trials of hy-
pothermia in stroke patients should not only care-
fully assess the incidence of pneumonia using a
standard definition but should also seek to minimize
this risk by careful use of sedative antishivering
medication, identifying biomarkers of developing
pneumonia, and instituting immediate treatment
when pneumonia is identified. The depth and
duration of cooling tested in a clinical trial should
seek the optimum balance between efficacy and
adverse effects, such as the development of infec-
tions.
Combination With Other Treatments for Acute Stroke
Any novel treatment for stroke should not affect the
delivery of other treatments known to be effective, or
alternatively should deliver greater efficacy than
those treatments they displace. For acute ischemic
stroke, there is good evidence for the efficacy of SU
care, aspirin, thrombolysis, and decompressive
hemicraniectomy (van der Worp and van Gijn,
2007; Donnan et al, 2008).
Stroke Unit Care: Transfer from an intensive care
setting to that of rehabilitation in an SU may be
slightly delayed by TH, depending on the modality
and duration of cooling. This is unlikely to be of
significance, particularly if cooling is delivered in an
environment experienced in the management of
stroke. Of greater potential significance is the delay
to the initiation of rehabilitation, wherein there is
some evidence to suggest that very early mobilization
(within 24hours of stroke onset) may convey addi-
tional benefits (Bernhardt et al, 2006; Sorbello et al,
2009), and this may be one of the mechanisms
through which the beneficial effects of SU care are
made manifest. Delays to the initiation of rehabilita-
tion may be attributed to active cooling (i.e., cooling
for 24 hours of longer), controlled rewarming (parti-
cularly in case of cooling to lower temperatures, in
which the rewarming phase may last up to 12hours),
or may be a consequence of the groin puncture
required for endovascular cooling. The benefits of
very early mobilization are currently being tested in a
randomized controlled trial (Bernhardt et al, 2006),
and these will have to be taken into account when
considering the potential benefits of hypothermia.
Aspirin: Both hypothermia and aspirin may be
associated with increased risk of gastric ulceration
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(Krieger et al, 2001; Baigent et al, 2009) and of
coagulopathy, but the extent to which this might be
clinically significant is not known. The benefits of
immediate aspirin are limited, and in patients
receiving thrombolysis, aspirin is not administered
in the first 24 hours; hence, if there is evidence of
increased risk in patients receiving aspirin and
hypothermia, then it would be reasonable to omit
aspirin for the duration of cooling. Unfortunately, the
randomized controlled trials of hypothermia in cardi-
ac arrest did not report whether those studies included
taking aspirin, and if so whether this had any effect
on outcome (HACA, 2002; Bernard et al, 2002).
Thrombolysis: Therapeutic thrombolysis depends
on the activity of a series of enzymes including rt-PA
itself and plasmin, and enzyme activity may be
exquisitely sensitive to temperature. The effect of
temperature on the efficacy of rt-PA has been
examined both in vitro and in vivo. Taking all the
in vitro data together (Figure 5), there seems to be a
relative decrease in lytic activity of B5% per degree
of hypothermia, equivalent to a 20% reduction in
activity with cooling to 331C (Yenari et al, 1995;
Schwarzenberg et al, 1998; Shaw et al, 2006, 2007).
However, given that rt-PA is likely to be administered
to eligible patients as soon as is practicable (and at or
before the initiation of cooling), it is unlikely that
such target temperatures would be achieved when
most lysis is occurring. Furthermore, in vivo studies
have suggested no effect of hypothermia on mortality
or reperfusion, and probably improved infarct
volume compared with thrombolysis of hypothermia
alone (Meden et al, 1994ab; Kollmar et al, 2004).
Endovascular cooling involves femoral puncture
and instrumentation of the inferior vena cava; this
might present problems if the puncture was to be
performed when lytic activity was at its height, or if
rt-PA administration was delayed until a femoral
catheter was established. However, such considera-
tions are not seen as an impediment to intraarterial
lysis and clot retrieval in patients who have received
intravenous rt-PA (Khatri et al, 2008); therefore,
although such considerations may favor the adoption
of a surface rather than endovascular approach to
cooling, they cannot be seen as an absolute contra-
indication to endovascular induction of hypothermia
in patients receiving intravenous rt-PA.
Decompressive Hemicraniectomy: In patients with
space-occupying MCA infarction, decompressive
hemicrainectomy leads to substantial improvements
in survival and functional outcome (Vahedi et al,
2007). Although surgery might be considered to be
associated with greater risks, particularly of hemor-
rhage or infection, in the context of hypothermia, this
does not seem to be the case, and indeed the
induction of hypothermia is considered by some to
be a useful adjunct to decompressive hemicraniect-
omy, and is the subject of ongoing studies (Poca et al,
2010).
Problems With Sample Size Calculation for Studies
In any clinical trial program, there are competing
ethical imperatives to ensure first that sufficient
patients are included to obtain a robust and precise
estimate of treatment effects and second that trials
are not unnecessarily large, continuing to allocate
patients to a treatment when the presence or absence
of efficacy is already known. These competing
demands can be resolved first through the use of
sample size calculations which use plausible and
realistic estimates of treatment effect sizes, and of
likely patient losses to follow-up, withdrawals from
active treatment, and crossing over between treat-
ment groups, and second through the staging of
preplanned interim analyses by an independent data
and safety monitoring committee, with clearly
defined procedures for when they would recommend
that a study be halted before full recruitment being
achieved, on the basis of safety (i.e., hazard), efficacy
(i.e., benefit), or futility.
Where trials in hypothermia test a range of
interventions, this situation is made more complex
by the substantial heterogeneity and lack of con-
sensus regarding the optimal depth and duration of
hypothermia, the different technologies that are
available to achieve hypothermia, and the different
shivering strategies that might be proposed. These
factors are likely to influence not only the efficacy of
the intervention but also the adverse effects. For
instance, endovascular cooling to 321C for 72hours
might be expected to be more effective than surface
cooling to 351C for 12hours, but would also be
expected to be associated with greater hazard.
There are two broad approaches to clinical trial
program design which might be used to address
these issues. A number of pilot studies are planned
or are in progress, testing different means, depths,
Figure 5 Effect of temperature on the in vitro lytic activity of tPA.
Linear regression gives r2=0.348, suggesting a 4.7% decline in
thrombolytic activity per degree of hypothermia. Data were
obtained from the studies by Yenari et al (1995), Schwarzenberg
et al (1998), Shaw et al (2006), and Shaw et al (2007).
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and durations of hypothermia. These will give some
information about the safety of different approaches,
but will allow only indirect comparison between the
different approaches and so will need to be inter-
preted with caution. However, they will provide
patient data with which it might be possible to test
whether there is any benefit of cooling independent
of means, depth, and duration. Such a meta-analysis
would be most powerful if the protocols of pilot
studies were aligned to minimize unnecessary
heterogeneity in trial design and if the definitions
used in data collection were uniform. There is a
precedent for this type of meta-analysis from the
decompressive hemicraniectomy trial lists (Vahedi
et al, 2007), and we propose that in the case of
planned and ongoing hypothermia studies, it might
be possible to go so far as having common trial
infrastructures such as electronic Case Report Forms
(eCRF) systems and a common data and safety
monitoring board.
Second, a major problem in this field of research is
the evolution of both cooling technologies and
management strategies (for instance, for shivering)
over time. One response to this which has been used
in other domains is the use of adaptive trial designs,
whereby the various treatment groups available, and
the planned size of each individual treatment group,
can be adjusted during the course of the trial. The
hypothesis herein relates not so much to relative
efficacy of different depths and durations of hy-
pothermia (although this might be possible) but
rather to selecting the intervention which is best
tolerated, which has fewest associated adverse
events, and which results in a brain temperature
closest to the target. If a new cooling strategy
becomes available during the course of the trial
which seems better against these criteria, than that
currently in use, or if a safer, more effective cooling
strategy becomes available, it would be possible to
adjust the trial protocol according to prespecified
rules and prespecified limits.
The Cochrane review of physical cooling methods
suggests that hypothermia may be associated with an
odds ratio for an improvement in outcome of 0.85
(Den Hertog et al, 2009a); if death and dependency
were seen in 50% of the control group, then 700
patients per group would be required to give 80%
power to detect such a difference using a dichot-
omous outcome measure, and assuming that 20% of
patients cross over or do not complete treatment, a
trial would require 1,750 patients; 90% power would
require 2,310 patients. However, the review included
data from just two physical cooling trials (of which
only one randomized), in a total of 59 patients. In
addition, the two studies were feasibility studies,
with time windows for start of treatment of up to
12hours. The benefit of hypothermia may therefore
be completely different from that suggested by the
Cochrane review.
It has been suggested (Bath et al, 2007) that the use
of a sliding dichotomous outcome may reduce the
required patient numbers byB30%, but this may not
be appropriate where treatment may be associated
with increased harm in some patients, as is seen with
thrombolysis and may also be the case with
hypothermia.
Conclusions
Next to reperfusion strategies, TH is the most
promising treatment for patients with acute ischemic
stroke. At present, clinical data on the use of
hypothermia in these patients are very limited and
do not provide sufficient information on potential
efficacy to support its use outside clinical trials. The
effect of hypothermia on functional outcome in
stroke is a priority question to be tested in large
randomized clinical trials, but given the limited
potential for commercial exploitation, it is likely that
such trials will be investigator driven.
The translational difficulties previously encoun-
tered in testing other potentially neuroprotective
interventions will be diminished by a more detailed
understanding of the most appropriate target depth
and duration of cooling, along with the optimization
of the means of cooling, the management of potential
complications including shivering and infections,
and increased understanding of how hypothermia
might interact with existing treatments. The Euro-
Hyp investigators are coordinating a number of small
pilot studies addressing these issues to inform the
design of a pan European multicenter randomized
controlled trial.
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